Showing 201 - 220 results of 532 for search '(( 19 a decrease ) OR ( 5 ((((meer decrease) OR (greater decrease))) OR (mean decrease)) ))', query time: 0.21s Refine Results
  1. 201
  2. 202
  3. 203
  4. 204
  5. 205
  6. 206
  7. 207
  8. 208

    Acute mercury toxicity modulates cytochrome P450, soluble epoxide hydrolase and their associated arachidonic acid metabolites in C57Bl/6 mouse heart by Amara, Issa E.A.

    Published 2014
    “…Our results showed that mercury treatment caused a significant induction of the cardiac hypertrophy markers, atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP); in addition to Cyp1a1, Cyp1b1, Cyp2b9, Cyp2b10, Cyp2b19, Cyp2c29, Cyp2c38, Cyp4a10, Cyp4a12, Cyp4a14, Cyp4f13, Cyp4f15, Cyp4f16 and Cyp4f18 gene expression. …”
    Get full text
    Get full text
  9. 209
  10. 210

    Investigation of flexible polymer-Tl2O3 nanocomposites for x-ray detector applications by Al-Sulaiti L.A.

    Published 2019
    “…The nanoparticles are synthesized using a microwave assisted technique under controlled temperature and pressure, and their average size is 13.0 ∓ 1.9 nm. …”
    Get full text
    Get full text
  11. 211

    Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 co... by Alize J, Ferrari

    Published 2024
    “…Non-communicable diseases contributed 1·73 billion (95% UI 1·54–1·94) DALYs in 2021, with a decrease in age-standardised DALY rates since 2010 of 6·4% (95% UI 3·5–9·5). …”
    Get full text
    Get full text
    Get full text
  12. 212

    Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 co... by Alize J, Ferrari

    Published 2024
    “…Non-communicable diseases contributed 1·73 billion (95% UI 1·54–1·94) DALYs in 2021, with a decrease in age-standardised DALY rates since 2010 of 6·4% (95% UI 3·5–9·5). …”
    Get full text
    Get full text
    Get full text
    article
  13. 213
  14. 214
  15. 215

    EPIDEMIOLOGY OF CHLAMYDIA TRACHOMATIS IN LATIN AMERICA AND THE CARIBBEAN: SYSTEMATIC REVIEW, META-ANALYSES, AND META-REGRESSIONS by ABU-EL-RUZ, RASHA

    Published 2022
    “…We conducted random-effects meta-regressions to identify sources of heterogeneity and possible predictors of high prevalence. Results: The pooled-mean urogenital CT prevalence was 8.2% (95% CI: 7.5-9.1) for general populations, 14.0% (95%CI: 12.7-15.4) for female sex workers, 10.8% (95% CI: 8.4-13.4) for men who have sex with men, male sex workers, and transgenders, 16.1% (95% CI: 12.6-19.8) for symptomatic women, 25.4 (95% CI: 18.6-38.5) for symptomatic men, 9.7% (95%CI: 6.1-14) for HIV-positive individuals and individuals in HIV-discordant couples, and 11.9% (95 CI: 8.5-15.8) for STI clinic attendees. …”
    Get full text
  16. 216
  17. 217
  18. 218
  19. 219

    Effect of hyperlipidemia on ketoconazole-midazolam drug-drug interaction in rat by Hamdy, D. A.

    Published 2011
    “…Normolipidemic and hyperlipidemic rats were administered a single intravenous dose of MDZ (5 mg/kg) with or without a single oral dose of racemic KTZ (40 mg/kg). …”
    Get full text
    Get full text
  20. 220

    Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus by Dimitrios, Patoulias

    Published 2023
    “…They have demonstrated1 that empagliflozin treatment resulted in a significant decrease in pulse pressure (PP), mean arterial pressure (MAP) and cardiac workload, compared with placebo; at week 12, placebo-adjusted mean changes from baseline were − 2.5 mmHg for PP, − 2.2 mmHg for MAP and − 315 mmHg x beats per minute (bpm) for cardiac workload (p < 0.0001 for all). …”
    Get full text
    Get full text
    Get full text